Search
Search titles only
By:
Search titles only
By:
Log in
Register
Search
Search titles only
By:
Search titles only
By:
Menu
Install the app
Install
Forums
New posts
All threads
Latest threads
New posts
Trending threads
Trending
Search forums
What's new
New posts
New ads
New profile posts
Latest activity
Free Ads
Latest reviews
Search ads
Members
Current visitors
New profile posts
Search profile posts
Contact us
Latest ads
ඔයාගෙ Assignment හෝ Thesis එක හරියට හදාගමු
ErMurazor
Updated:
Saturday at 10:52 PM
Ad icon
BlackWall V2ray servers
hu KANNA
Updated:
Wednesday at 4:58 AM
Peppa Pig Family Plush Toy Set – 5 Characters
anil1961
Updated:
Sep 19, 2026
Ad icon
Express VPN PC - 1 Year Rs. 600.00
Sanathbh
Updated:
Sep 19, 2026
Ad icon
Capcut Pro 7 Days Team Plan - Rs. 3️⃣0️⃣0️⃣
Sanathbh
Updated:
Sep 19, 2026
Electronics
Vehicles
Property
Search
Reply to thread
Forums
General
News
Chinese firm buys Canada mRNA vaccine tech in US$500M deal
Get the App
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Message
<blockquote data-quote="KBE_KevinSpacey" data-source="post: 26969055" data-attributes="member: 577428"><p>Chinese biopharma firm Everest Medicines Ltd. will license an mRNA COVID-19 vaccine from Canada’s Providence Therapeutics Holdings Inc., as companies try to bring the most effective inoculation platform into China despite its apparent resistance to western shots. </p><p></p><p>Everest will gain rights to Providence’s vaccine in Greater China and countries including Indonesia, Singapore, and Thailand, it said in a statement Monday. It will pay US$100 million cash upfront for access to the vaccines and mRNA technology, and up to US$100 million in profit-sharing, the statement said. The deal includes another payment of up to US$300 million in stock if further products are developed using Providence’s mRNA technology platform. </p><p></p><p>While almost 1 billion people have been fully vaccinated in China, the country is still lacking an mRNA shot, with most of the population inoculated with inactivated vaccines from Sinopharm Group Co. and Sinovac Biotech Ltd., which studies have found to be less effective. A deal by Fosun Pharmaceutical Group Co. to sell BioNTech SE’s mRNA shot in mainland China has yet to be approved by regulators, suggesting it may not be easy to bring in a foreign mRNA vaccine, partly because of political sensitivities. </p><p></p><p>If approved, the Everest-Providence vaccine will likely be used as a booster shot in China given most of the population has been vaccinated, Everest Chief Executive Officer Kerry Blanchard said in an interview. In other Asian nation’s within Everest’s remit, there’s still the need for primary vaccination, he said.</p><p></p><p>“That’s still a large group of people,” Blanchard said. “I think it’s a reasonable assumption that most adults will likely need a booster at some point, and the older you are, the more rapidly the immunity wanes. People will need to have at least one booster.”</p><p></p><p>Everest’s full technology transfer of the Providence shot means the Chinese firm would have a bigger stake in the vaccine, which may potentially help its chances to be considered as a Chinese vaccine, compared to Fosun Pharma which would only manufacture and distribute the BioNTech jab. </p><p></p><p>source <a href="https://www.bnnbloomberg.ca/chinese-firm-buys-canada-mrna-vaccine-tech-in-500-million-deal-1.1651296" target="_blank">bnnbloomberg.ca</a></p></blockquote><p></p>
[QUOTE="KBE_KevinSpacey, post: 26969055, member: 577428"] Chinese biopharma firm Everest Medicines Ltd. will license an mRNA COVID-19 vaccine from Canada’s Providence Therapeutics Holdings Inc., as companies try to bring the most effective inoculation platform into China despite its apparent resistance to western shots. Everest will gain rights to Providence’s vaccine in Greater China and countries including Indonesia, Singapore, and Thailand, it said in a statement Monday. It will pay US$100 million cash upfront for access to the vaccines and mRNA technology, and up to US$100 million in profit-sharing, the statement said. The deal includes another payment of up to US$300 million in stock if further products are developed using Providence’s mRNA technology platform. While almost 1 billion people have been fully vaccinated in China, the country is still lacking an mRNA shot, with most of the population inoculated with inactivated vaccines from Sinopharm Group Co. and Sinovac Biotech Ltd., which studies have found to be less effective. A deal by Fosun Pharmaceutical Group Co. to sell BioNTech SE’s mRNA shot in mainland China has yet to be approved by regulators, suggesting it may not be easy to bring in a foreign mRNA vaccine, partly because of political sensitivities. If approved, the Everest-Providence vaccine will likely be used as a booster shot in China given most of the population has been vaccinated, Everest Chief Executive Officer Kerry Blanchard said in an interview. In other Asian nation’s within Everest’s remit, there’s still the need for primary vaccination, he said. “That’s still a large group of people,” Blanchard said. “I think it’s a reasonable assumption that most adults will likely need a booster at some point, and the older you are, the more rapidly the immunity wanes. People will need to have at least one booster.” Everest’s full technology transfer of the Providence shot means the Chinese firm would have a bigger stake in the vaccine, which may potentially help its chances to be considered as a Chinese vaccine, compared to Fosun Pharma which would only manufacture and distribute the BioNTech jab. source [URL='https://www.bnnbloomberg.ca/chinese-firm-buys-canada-mrna-vaccine-tech-in-500-million-deal-1.1651296']bnnbloomberg.ca[/URL] [/QUOTE]
Insert quotes…
Verification
Hath warak paha keeyada? (hatha wadikireema paha)
Post reply
Top
Bottom